市場調査レポート

次世代シーケンシングによる勢い:市場は技術と技術革新に反応

Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances

発行 Insight Pharma Reports 商品コード 199300
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
次世代シーケンシングによる勢い:市場は技術と技術革新に反応 Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances
出版日: 2011年06月07日 ページ情報: 英文
概要

当レポートでは、次世代シーケンシングシステムの概要と開発中の技術革新動向、装置およびサービス動向、6名の専門家インタビュー、今後の発展予測などをまとめ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

第1章 イントロダクション

第2章 次世代シーケンシングの発展

  • 従来のシーケンシングと早期の応用
  • ヒトゲノムプロジェクト
  • 第1世代シーケンシング
  • オミクスの時代と遺伝子・疾患との関係調査
  • 次世代シーケンサーの源と早期の発展

第3章 最新動向

  • 現在上市されている、または近々上市されるシステムの性能比較
  • バイオインフォマティクス
  • 試料調製

第4章 近い将来登場するシステムと技術

  • 企業プログラム
    • Illumina Avantome
    • Oxford Nanopore Technologies
    • Electronic Bio Sciences
    • General Electric Global Research
    • GnuBio
    • BioNanomatrix
    • Halcyon Molecular
    • IBM
    • Intelligent Bio-Systems
    • Life Technologies Starlight
    • LightSpeed Genomics
    • NABsys
    • NobleGen
    • ZS Genetics
  • 学術機関の貢献
    • グラフェンナノ細孔
    • その他

第5章 市場動向

  • 2011年までのシーケンシング市場における競合環境
  • 2012年までの起こりうるシナリオ
  • 次世代シーケンシングの診断への応用見通し
  • 契約と契約形態
  • ユーザー調査結果と考察
    • 回答者の識別
    • 次世代シーケンシング活動の性質
    • インフォマティクス
    • シーケンサーの特性

第6章 結論と動向

  • シーケンシング:次世代
  • 次世代シーケンシングの展開医療の側面
    • 試料の取り扱い
    • データの取り扱い

第7章 インタビュー

目次

This report focuses on current and innovative NGS technologies, services and markets to answer such questions as;

  • Which early NGS market entrants have been continually improving and updating their original systems?
  • Who has introduced new scaled-down instruments to broaden the market?
  • What Generation 2.5 systems featuring new detection technologies and single-molecule sequencing are now on the market?
  • When will third generation of instruments led by nanopore technologies be entering the commercial feasibility stage?
  • Why upstream sample handling is undergoing continual technological innovation?
  • Which informatics providers are moving rapidly toward fully integrated systems to provide the rapid generation of actionable biological information?

Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances describes these innovations and analyzes their impact on this extremely dynamic technology and market sector.

We report on the:

  • NGS systems on the market and those on the horizon
  • Possible game changing innovations still in development
  • NGS market dynamics for instruments and services
  • Results of an Insight Pharma Reports' user market survey
  • Interviews with six experts on diverse aspects of NGS
  • Analysis on how the field will likely develop over the next several years.

Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances updates the product offerings from Roche/454, Illumina, Life Technologies (Ion Torrent), Complete Genomics (CGI), Helicos, Pacific Biosciences (PacBio). As well as NGS upstream sample preparation and downstream informatics, aspects of NGS that have developed into substantial and fast-growing markets of their own. Companies in the informatics space covered in this report include Geospiza, Accelrys, GenoLogics, CLC bio, GenomeQuest, Partek, and DNAStar and Ingenuity Systems.

Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances looks at a number of new product and technology candidates in varying stages of development. As the report highlights, some candidates are mainly extensions of current technologies, while others represent something very different.

Large companies have entered the new technology race such as General Electric, IBM as well as Life Technologies with its Starlight system. Many small entrepreneurial companies are also covered in this report including GnuBio' s with its microreactors, Halcyon Molecular and ZS Genetics' use of scanning transmission electron microscopy, Intelligent Bio-Systems' 40 million five micron wells, NABsys, using a hybridization-assisted nanopore method, NobleGen' s approach involving preliminary replacement of each base by longer oligonucleotides prior to sequencing and LightSpeed Genomics where patents suggest involving novel optical scanning methodology.

Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances investigates the market dynamics where Illumina, Life Technologies, and Roche currently dominate a sequencer market now estimated to exceed $1 billion per year. It' s a market where companies are making continual advances in cost and performance at a pace exceeding that associated with semiconductor technology, where market adoption, application diversity, and implications for life science research continue to advance.

  • Learn from this report the answers to such questions as:
  • Why is Illumina the clear market leader, accounting for about 60% of revenues?
  • Who are the key players in the NGS services market for now?
  • What' s attractive about Pacific Biosciences' single-molecule sequencer?
  • What will be the impact of low-cost systems?
  • Will the market expand into clinical diagnostic applications?

About the Author

Ken Rubenstein, PhD, a biochemist and molecular biologist, received his PhD at the University of Wisconsin and postdoctoral training at the University Of Pennsylvania School Of Medicine. He was a key innovator and research manager for Syva Company, the diagnostics branch of Syntex Corporation. During his 13 years with Syva, Dr. Rubenstein became vice president, scientific affairs, and a function that included strategic planning. Since 1983, he has served as a technology and marketing consultant to biomedical companies and an industry analyst, with more than 40 published studies to his credit.

Table of Contents

Executive Summary

Evolution of NGS technologies

State of the art

Systems and technologies on the horizon

Market dynamics

Chapter - 1

INTRODUCTION

  • 1.1 Scope and contents of this report

Chapter - 2

EVOLUTION OF NGS

  • 2.1 Classical sequencing and early applications
  • 2.2 The Human Genome Project
  • 2.3 First generation sequencing
  • 2.4 The Omics Era and the search for gene-disease associations
  • 2.5 Origins and early development of next-generation sequencers

Chapter - 3

STATE OF THE ART

  • Technologies Currently On, or Very Near, the Market
  • Illumina
  • Life Technologies
  • Complete Genomics
  • Roche/454 Life Sciences
  • Helicos BioSciences
  • Pacific Biosciences
  • Ion Torrent
  • 3.2 Comparative performance of systems currently on the market or nearly so
  • 3.3 Bioinformatics
  • 3.4 Sample Preparation

Chapter - 4

SYSTEMS AND TECHNOLOGIES ON THE HORIZON

This chapter deals with new sequencing technologies and systems still in research or under development. Some can reasonably be considered extensions of second-generation technologies, but others represent a potential great leap forward in performance and cost-effectiveness. For the most part, methods in the second category face significant conceptual and practical difficulties, and have not yet crossed the commercial feasibility barrier. After considering companies active in this area, we review some notable academic research, some of it done in collaboration with corporate partners.

  • 4.1 Corporate programs
  • Illumina Avantome
  • Oxford Nanopore Technologies
  • Electronic Bio Sciences
  • General Electric Global Research
  • GnuBio
  • BioNanomatrix
  • Halcyon Molecular
  • IBM
  • Intelligent Bio-Systems
  • Life Technologies Starlight
  • LightSpeed Genomics
  • NABsys
  • NobleGen
  • ZS Genetics
  • 4.2 Academic contributions
  • Graphene Nanopores
  • Other nanopore work

Chapter - 5

MARKET DYNAMICS

  • 5.1 Competitive environment in the sequencing market through 2011
  • 5.2 Possible scenario through 2012
  • 5.3 Prospects for diagnostic applications of NGS
  • 5.4 Deals and deal patterns
  • 5.5 User survey results and discussion
  • Identification of respondents
  • Nature of NGS activities
  • Informatics activities
  • Sequencer attributes

Chapter - 6

CONCLUSIONS AND TRENDS

  • 6.1 Sequencing - The Next Generation
  • 6.2 Translational medicine aspects of NGS
  • Sample handling
  • Data handling

Chapter - 7

INTERVIEW TRANSCRIPTS

  • Geoffrey Barrall, Ph.D., President, Electronic BioSciences
  • Stephen Turner, Ph.D., Founder and CTO, Pacific Biosciences
  • Clifford Baron, Director Biology Product Marketing, Accelrys
  • Clifford Reid, Ph.D., Co-founder, President, CEO, and Chairman, Complete Genomics
  • Jeffery Schloss, Ph.D., Program Director, U.S. National Human Genome Research Institute
  • Todd Smith, CTO, Geospiza
Back to Top